Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 5/20 | 0.51 |
| ▸ | GSK3A | P49840 | 4/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RGS4 | P49798 | 2/20 | 0.42 |
| ▸ | RGS8 | P57771 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | CTSG | P08311 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9392938 | 0.84 | TSHR (0.45) | GSK3BGSK3AKMT2AMEN1LMNA | |
| SCHEMBL4763629 | 0.83 | HTT (0.46) | HPGDCYP3A4KMT2AMEN1ALDH1A1 | |
| SCHEMBL5800712 | 0.80 | HPGD (0.49) | HPGDGSK3BGSK3ACCNB2CDK1 | |
| SCHEMBL12214476 | 0.79 | ALDH1A1 (0.47) | HPGDGSK3BGSK3ACCNB2CDK1 | |
| SCHEMBL7750738 | 0.79 | HPGD (0.51) | HPGDGSK3BGSK3ACCNB2CDK1 | |
| SCHEMBL1584773 | 0.79 | HPGD (0.47) | HPGDGSK3BGSK3ACCNB2CDK1 | |
| SCHEMBL7519636 | 0.78 | KMT2A (0.52) | HPGDGSK3BGSK3ACCNB2CDK1 | |
| SCHEMBL8301883 | 0.78 | SMN1; SMN2 (0.47) | HPGDGSK3BGSK3ACCNB2CDK1 | |
| SCHEMBL30272686 | 0.77 | HPGD (0.50) | HPGDGSK3BGSK3ACCNB2CDK1 | |
| SCHEMBL9392329 | 0.77 | PARG (0.37) | HPGDGSK3BGSK3ACCNB2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0891336-B1 | SUBSTITUTED 1-METHYL-3-BENZYLURACILS | BASF AG (DE) | 2002-06-05 | — | — | EP | claimed |
| EP-0891336-A1 | SUBSTITUTED 1-METHYL-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1999-01-20 | — | — | EP | claimed |
| WO-1997035845-A1 | SUBSTITUTED 1-METHYL-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1997-10-02 | — | — | WO | claimed |
| US-20210220331-A1 | INHIBITORS OF IRES-MEDIATED PROTEIN SYNTHESIS | THE UNITED STATES GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2021-07-22 | — | — | US | disclosed |
| EP-3452447-A1 | INHIBITORS OF IRES-MEDIATED PROTEIN SYNTHESIS | The Regents of The University of California (US) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017192665-A1 | INHIBITORS OF IRES-MEDIATED PROTEIN SYNTHESIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-09 | — | — | WO | disclosed |
| EP-0891336-B1 | SUBSTITUTED 1-METHYL-3-BENZYLURACILS | BASF AG (DE) | 2002-06-05 | — | — | EP | disclosed |
| EP-0891336-B1 | SUBSTITUTED 1-METHYL-3-BENZYLURACILS | BASF AG (DE) | 2002-06-05 | — | — | EP | disclosed |
| EP-0835248-B1 | 1-AMINO-3-BENZYLURACILS | BASF AG (DE) | 2001-02-21 | — | — | EP | disclosed |
| EP-0971904-A1 | NOVEL 1-AMINO-3 BENZYL URACILS | BASF AKTIENGESELLSCHAFT (DE) | 2000-01-19 | — | — | EP | disclosed |
| EP-0891336-A1 | SUBSTITUTED 1-METHYL-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1999-01-20 | — | — | EP | disclosed |
| EP-0891336-A1 | SUBSTITUTED 1-METHYL-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1999-01-20 | — | — | EP | disclosed |
| WO-1998042682-A1 | NOVEL 1-AMINO-3 BENZYL URACILS | BASF AKTIENGESELLSCHAFT (DE) | 1998-10-01 | — | — | WO | disclosed |
| CN-1189824-A | 1-amino-3-benzyluracils | BASF AG (DE) | 1998-08-05 | — | — | CN | disclosed |
| EP-0835248-A1 | 1-AMINO-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1998-04-15 | — | — | EP | disclosed |
| WO-1997035845-A1 | SUBSTITUTED 1-METHYL-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1997-10-02 | — | — | WO | disclosed |
| WO-1997035845-A1 | SUBSTITUTED 1-METHYL-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1997-10-02 | — | — | WO | disclosed |
| WO-1997001543-A1 | 1-AMINO-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1997-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220331-A1 | INHIBITORS OF IRES-MEDIATED PROTEIN SYNTHESIS | EIF4EBP1, EIF4E, EIF2A | HPGD 3898/4885GSK3B 772/4885GSK3A 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.